Stockholders’ Equity - Schedule of Outstanding Number of Warrants (Details) - Warrant [Member] - $ / shares |
3 Months Ended | |
|---|---|---|
Mar. 31, 2026 |
Mar. 31, 2025 |
|
| Schedule of Outstanding Number of Warrants [Line Items] | ||
| Number of warrants, Outstanding beginning balance | 13,907,295 | 10,841,482 |
| Weighted Average, Outstanding beginning balance | $ 1.97 | $ 1.17 |
| Number of warrants, Granted | 12,893,650 | |
| Weighted Average Exercise Price, Granted | $ 1.3 | |
| Number of warrants, Outstanding ending balance | 13,907,295 | 23,735,132 |
| Weighted Average, Outstanding ending balance | $ 1.97 | $ 1.24 |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Net number of non-option equity instruments granted to participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of equity instruments other than options outstanding, including both vested and non-vested instruments. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|